Venus Remedies has received European Union patent for its researched anti-infection product 'Sulbactomax'. According to a company announcement, the patent granted by European Patent Organisation (EPO) covers the entire EU region.
Sulbactomax is capable of replacing a larger share of ceftriaxone market, which is a preferred antibiotic till now, said the company in a stock exchange announcement. This is also India's first
researched anti-infection product for catering bacterial resistance to get EU patent, it added.
The company plans to enter the EU market through CTD (common technical document) route and will be able to launch the product by 2013. The patent is valid until November 2025. The company
is also considering tie-ups with multinational companies for out licencing the product in geographies where it holds the patent for Sulbactomax.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app